Literature DB >> 16807911

Childhood multiple sclerosis: a review.

Amy Waldman1, Erin O'Connor, Gihan Tennekoon.   

Abstract

Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system (CNS) that is increasingly recognized as a disease that affects children. Similar to adult-onset MS, children present with visual and sensory complaints, as well as weakness, spasticity, and ataxia. A lumbar puncture can be helpful in diagnosing MS when CSF immunoglobulins and oligoclonal bands are present. White matter demyelinating lesions on MRI are required for the diagnosis; however, children typically have fewer lesions than adults. Many criteria have been proposed to diagnose MS that have been applied to children, mostly above 10 years of age. The recent revisions to the McDonald criteria allow for earlier diagnosis, such as after a clinically isolated event. However, children are more likely than adults to have monosymptomatic illnesses. None of the approved disease-modifying therapies used in adult-onset MS have been approved for pediatrics; however, a few studies have verified their safety and tolerability in children. Although children and adults with MS have similar neurological symptoms, laboratory (cerebrospinal fluid) data, and neuroimaging findings, the clinical course, pathogenesis, and treatment of childhood onset MS require further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807911      PMCID: PMC7168360          DOI: 10.1002/mrdd.20105

Source DB:  PubMed          Journal:  Ment Retard Dev Disabil Res Rev        ISSN: 1080-4013


  88 in total

1.  Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

Authors:  D S Goodin; E M Frohman; G P Garmany; J Halper; W H Likosky; F D Lublin; D H Silberberg; W H Stuart; S van den Noort
Journal:  Neurology       Date:  2002-01-22       Impact factor: 9.910

Review 2.  Na+ channel expression along axons in multiple sclerosis and its models.

Authors:  Stephen G Waxman; Matthew J Craner; Joel A Black
Journal:  Trends Pharmacol Sci       Date:  2004-11       Impact factor: 14.819

3.  Overview of azathioprine treatment in multiple sclerosis.

Authors:  P L Yudkin; G W Ellison; A Ghezzi; D E Goodkin; R A Hughes; K McPherson; J Mertin; C Milanese
Journal:  Lancet       Date:  1991-10-26       Impact factor: 79.321

4.  Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.

Authors:  A Ghezzi; M P Amato; M Capobianco; P Gallo; G Marrosu; V Martinelli; N Milani; C Milanese; L Moiola; F Patti; V Pilato; C Pozzilli; M Trojano; M Zaffaroni; G Comi
Journal:  Mult Scler       Date:  2005-08       Impact factor: 6.312

5.  Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

Authors:  T Moreau; A Coles; M Wing; J Isaacs; G Hale; H Waldmann; A Compston
Journal:  Brain       Date:  1996-02       Impact factor: 13.501

6.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

7.  Statins as immunomodulators: comparison with interferon-beta 1b in MS.

Authors:  O Neuhaus; S Strasser-Fuchs; F Fazekas; B C Kieseier; G Niederwieser; H P Hartung; J J Archelos
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

8.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

9.  Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.

Authors:  Rina Aharoni; Basak Kayhan; Raya Eilam; Michael Sela; Ruth Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-12       Impact factor: 11.205

10.  Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo.

Authors:  Albert C Lo; Carl Y Saab; Joel A Black; Stephen G Waxman
Journal:  J Neurophysiol       Date:  2003-08-06       Impact factor: 2.714

View more
  2 in total

Review 1.  Management of multiple sclerosis in adolescents - current treatment options and related adherence issues.

Authors:  Jean K Mah; Jennifer E Thannhauser
Journal:  Adolesc Health Med Ther       Date:  2010-06-17

2.  Promising candidate cerebrospinal fluid biomarkers of seizure disorder, infection, inflammation, tumor, and traumatic brain injury in pediatric patients.

Authors:  Seh Hyun Kim; Soo Ahn Chae
Journal:  Clin Exp Pediatr       Date:  2021-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.